Mixing it up: boosting responses with immunotherapy combinations.

IF 14.3 1区医学 Q1 ONCOLOGY

Trends in cancer Pub Date : 2025-06-01 Epub Date: 2025-05-06 DOI:10.1016/j.trecan.2025.04.013

Hiroki Komatsuda, Edward S Sim, Ravindra Uppaluri

引用次数: 0

Abstract

Whether combination neoadjuvant immunotherapy can enhance response in patients with head and neck cancer remains unclear. Recently, Li et al. demonstrated improved responses with neoadjuvant anti-PD-1+CTLA-4 or anti-PD-1+LAG-3 compared with anti-PD-1 monotherapy. These combination strategies act via different mechanisms with distinct biomarkers of response, highlighting the potential for personalized neoadjuvant immunotherapy approaches.

查看原文本刊更多论文

混合：用免疫疗法组合来增强反应。

联合新辅助免疫治疗是否能提高头颈癌患者的应答尚不清楚。最近，Li等人证明，与单药治疗相比，新辅助抗pd -1+CTLA-4或抗pd -1+LAG-3治疗的疗效更好。这些组合策略通过不同的机制与不同的生物标志物起作用，突出了个性化新辅助免疫治疗方法的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Trends in cancer Medicine-Oncology

CiteScore

28.50

自引率

0.50%

发文量

138

期刊介绍： Trends in Cancer, a part of the Trends review journals, delivers concise and engaging expert commentary on key research topics and cutting-edge advances in cancer discovery and medicine. Trends in Cancer serves as a unique platform for multidisciplinary information, fostering discussion and education for scientists, clinicians, policy makers, and patients & advocates.Covering various aspects, it presents opportunities, challenges, and impacts of basic, translational, and clinical findings, industry R&D, technology, innovation, ethics, and cancer policy and funding in an authoritative yet reader-friendly format.